GTx Files Toremifene For Prostate Cancer-Related Bone Loss
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
GTx is looking to be first to market with a treatment for prostate cancer patients that helps prevent common and debilitating fractures caused by androgen deprivation therapy.
You may also be interested in...
Amgen Submits Denosumab BLA Ahead Of Expectations
Novel RANK ligand inhibitor could have Oct. 19, 2009, PDUFA date.
GTx Closer To Filing NDA For Acapodene With Promising Phase III Results
Reduced vertebral fracture risk means the selective androgen receptor modulator could offer median survival improvement
Rare Disease Roundtable: Dealing With Pricing Pressure
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.